ORAMED PHARMACEUTICALS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
ORAMED PHARMACEUTICALS INC. (ORMP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 of $905.24 thousand for the 12-month period ending 2013-08-31, per its 10-K filed 2013-11-27.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 · last filed 2013-11-27
- ORAMED PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2013 was $905.24K, a 135.39% increase from fiscal 2012.
- ORAMED PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2012 was $384.56K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month as first filed |
|---|---|---|
| 2013-08-31 | $905.24K 10-K · filed 2013-11-27 | |
| 2012-08-31 | $384.56K 10-K · filed 2013-11-27 | -$384.56K 10-K · filed 2012-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |